These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

359 related articles for article (PubMed ID: 23751282)

  • 1. Rational Helicobacter pylori therapy: evidence-based medicine rather than medicine-based evidence.
    Graham DY; Lee YC; Wu MS
    Clin Gastroenterol Hepatol; 2014 Feb; 12(2):177-86.e3; Discussion e12-3. PubMed ID: 23751282
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A randomized trial of lansoprazole, amoxycillin, and clarithromycin versus lansoprazole, bismuth, metronidazole and tetracycline in the retreatment of patients failing initial Helicobacter pylori therapy.
    Magaret N; Burm M; Faigel D; Kelly C; Peterson W; Fennerty MB
    Dig Dis; 2001; 19(2):174-8. PubMed ID: 11549829
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Role of proton pump inhibitors dosage and duration in Helicobacter pylori eradication treatment: Results from the European Registry on H. pylori management.
    Pabón-Carrasco M; Keco-Huerga A; Castro-Fernández M; Saracino IM; Fiorini G; Vaira D; Pérez-Aísa Á; Tepes B; Jonaitis L; Voynovan I; Lucendo AJ; Lanas Á; Martínez-Domínguez SJ; Almajano EA; Rodrigo L; Vologzanina L; Brglez Jurecic N; Denkovski M; Bujanda L; Abdulkhakov RA; Huguet JM; Fernández-Salazar L; Alcaide N; Velayos B; Silkanovna Sarsenbaeva A; Zaytsev O; Ilchishina T; Barrio J; Bakulin I; Perona M; Alekseenko S; Romano M; Gravina AG; Núñez Ó; Gómez Rodríguez BJ; Ledro-Cano D; Pellicano R; Bogomolov P; Domínguez-Cajal M; Almela P; Gomez-Camarero J; Bordin DS; Gasbarrini A; Kupčinskas J; Cano-Català A; Moreira L; Nyssen OP; Mégraud F; O'Morain C; Gisbert JP;
    United European Gastroenterol J; 2024 Feb; 12(1):122-138. PubMed ID: 38050339
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Toronto Consensus for the Treatment of Helicobacter pylori Infection in Adults.
    Fallone CA; Chiba N; van Zanten SV; Fischbach L; Gisbert JP; Hunt RH; Jones NL; Render C; Leontiadis GI; Moayyedi P; Marshall JK
    Gastroenterology; 2016 Jul; 151(1):51-69.e14. PubMed ID: 27102658
    [TBL] [Abstract][Full Text] [Related]  

  • 5. 14-day triple, 5-day concomitant, and 10-day sequential therapies for Helicobacter pylori infection in seven Latin American sites: a randomised trial.
    Greenberg ER; Anderson GL; Morgan DR; Torres J; Chey WD; Bravo LE; Dominguez RL; Ferreccio C; Herrero R; Lazcano-Ponce EC; Meza-Montenegro MM; Peña R; Peña EM; Salazar-Martínez E; Correa P; Martínez ME; Valdivieso M; Goodman GE; Crowley JJ; Baker LH
    Lancet; 2011 Aug; 378(9790):507-14. PubMed ID: 21777974
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Randomized clinical trial comparing ten day concomitant and sequential therapies for Helicobacter pylori eradication in a high clarithromycin resistance area.
    Georgopoulos SD; Xirouchakis E; Martinez-Gonzales B; Zampeli E; Grivas E; Spiliadi C; Sotiropoulou M; Petraki K; Zografos K; Laoudi F; Sgouras D; Mentis A; Kasapidis P; Michopoulos S
    Eur J Intern Med; 2016 Jul; 32():84-90. PubMed ID: 27134145
    [TBL] [Abstract][Full Text] [Related]  

  • 7. High efficacy of 14-day triple therapy-based, bismuth-containing quadruple therapy for initial Helicobacter pylori eradication.
    Sun Q; Liang X; Zheng Q; Liu W; Xiao S; Gu W; Lu H
    Helicobacter; 2010 Jun; 15(3):233-8. PubMed ID: 20557366
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Concomitant, bismuth quadruple, and 14-day triple therapy in the first-line treatment of Helicobacter pylori: a multicentre, open-label, randomised trial.
    Liou JM; Fang YJ; Chen CC; Bair MJ; Chang CY; Lee YC; Chen MJ; Chen CC; Tseng CH; Hsu YC; Lee JY; Yang TH; Luo JC; Chang CC; Chen CY; Chen PY; Shun CT; Hsu WF; Hu WH; Chen YN; Sheu BS; Lin JT; Wu JY; El-Omar EM; Wu MS;
    Lancet; 2016 Nov; 388(10058):2355-2365. PubMed ID: 27769562
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Nonbismuth quadruple (concomitant) therapy: empirical and tailored efficacy versus standard triple therapy for clarithromycin-susceptible Helicobacter pylori and versus sequential therapy for clarithromycin-resistant strains.
    Molina-Infante J; Pazos-Pacheco C; Vinagre-Rodriguez G; Perez-Gallardo B; Dueñas-Sadornil C; Hernandez-Alonso M; Gonzalez-Garcia G; Mateos-Rodriguez JM; Fernandez-Bermejo M; Gisbert JP
    Helicobacter; 2012 Aug; 17(4):269-76. PubMed ID: 22759326
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Randomised controlled trial: susceptibility-guided therapy versus empiric bismuth quadruple therapy for first-line Helicobacter pylori treatment.
    Chen Q; Long X; Ji Y; Liang X; Li D; Gao H; Xu B; Liu M; Chen Y; Sun Y; Zhao Y; Xu G; Song Y; Yu L; Zhang W; Liu W; Graham DY; Lu H
    Aliment Pharmacol Ther; 2019 Jun; 49(11):1385-1394. PubMed ID: 31020673
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Helicobacter pylori first-line and rescue treatments in the presence of penicillin allergy.
    Gisbert JP; Barrio J; Modolell I; Molina-Infante J; Aisa AP; Castro-Fernández M; Rodrigo L; Cosme A; Gisbert JL; Fernández-Bermejo M; Marcos S; Marín AC; McNicholl AG
    Dig Dis Sci; 2015 Feb; 60(2):458-64. PubMed ID: 25236423
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A Randomized Controlled Trial Shows that both 14-Day Hybrid and Bismuth Quadruple Therapies Cure Most Patients with Helicobacter pylori Infection in Populations with Moderate Antibiotic Resistance.
    Tsay FW; Wu DC; Yu HC; Kao SS; Lin KH; Cheng JS; Wang HM; Chen WC; Sun WC; Tsai KW; Hsu PI
    Antimicrob Agents Chemother; 2017 Nov; 61(11):. PubMed ID: 28807915
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Neither 10- nor 14-Day Sequential Treatment is better than Standard Triple Therapy for Helicobacter Pylori Eradication.
    Warrington E; López-Román O; Tirado Montijo R; Urbina R; Cruz-Correa M; Toro DH
    P R Health Sci J; 2016 Dec; 35(4):203-208. PubMed ID: 27898166
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Bismuth improves efficacy of proton-pump inhibitor clarithromycin, metronidazole triple Helicobacter pylori therapy despite a high prevalence of antimicrobial resistance.
    Long X; Chen Q; Yu L; Liang X; Liu W; Lu H
    Helicobacter; 2018 Jun; 23(3):e12485. PubMed ID: 29696736
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Second-line rescue triple therapy with levofloxacin after failure of non-bismuth quadruple "sequential" or "concomitant" treatment to eradicate H. pylori infection.
    Gisbert JP; Molina-Infante J; Marin AC; Vinagre G; Barrio J; McNicholl AG
    Scand J Gastroenterol; 2013 Jun; 48(6):652-6. PubMed ID: 23556551
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A new look at anti-Helicobacter pylori therapy.
    Chuah SK; Tsay FW; Hsu PI; Wu DC
    World J Gastroenterol; 2011 Sep; 17(35):3971-5. PubMed ID: 22046084
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evidence-based recommendations for successful Helicobacter pylori treatment.
    Wu JY; Liou JM; Graham DY
    Expert Rev Gastroenterol Hepatol; 2014 Jan; 8(1):21-8. PubMed ID: 24410470
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Is tailored therapy based on antibiotic susceptibility effective ? a multicenter, open-label, randomized trial.
    Pan J; Shi Z; Lin D; Yang N; Meng F; Lin L; Jin Z; Zhou Q; Wu J; Zhang J; Li Y
    Front Med; 2020 Feb; 14(1):43-50. PubMed ID: 31907860
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of bismuth-containing quadruple therapies for clarithromycin-, metronidazole-, and fluoroquinolone-resistant Helicobacter pylori infections in a prospective study.
    Liang X; Xu X; Zheng Q; Zhang W; Sun Q; Liu W; Xiao S; Lu H
    Clin Gastroenterol Hepatol; 2013 Jul; 11(7):802-7.e1. PubMed ID: 23376004
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pylera and sequential therapy for first-line Helicobacter pylori eradication: a culture-based study in real clinical practice.
    Fiorini G; Zullo A; Saracino IM; Gatta L; Pavoni M; Vaira D
    Eur J Gastroenterol Hepatol; 2018 Jun; 30(6):621-625. PubMed ID: 29481383
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 18.